NCT01042717UnknownNot Applicable
Mobilization Kinetics of Plerixafor and G-CSF in Patients With NHL and MM Undergoing Autologous Peripheral Blood Progenitor Cell Collection
Shi, Patricia, M.D.1 site in 1 country10 target enrollmentStarted: February 2010Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Enrollment
- 10
- Locations
- 1
- Primary Endpoint
- Percent of donors obtaining a minimum CD34+ cell dose of 2 x 106/kg actual recipient weight within 2 days of collection
Study Overview
Brief Summary
The purpose of this study is to determine whether it is safe and effective to collect peripheral blood hematopoietic stem cells 16 hours rather than the usual 11 hours after administration of plerixafor.
Detailed Description
The current FDA-approved timing for plerixafor is approximately 11 hours prior to apheresis. This is a logistical problem, since plerixafor should be administered by a health care provider, given the risk of hypotension with administration. The primary purpose of this study is, in autologous donors with non-Hodgkins lymphoma and multiple myeloma undergoing hematopoietic progenitor cell mobilization with plerixafor and G-CSF, to determine whether the dosing interval can be increased to 16 hours prior to apheresis. Patients will be admitted to a special clinical research center on the 4th day of G-CSF administration, where the peripheral blood CD34+ count will be measured every 2 hours after plerixafor administration at 5 pm until 9 AM the following day, at which time apheresis will commence. The hypothesis is that plerixafor administration 16 hours prior to apheresis is as safe and effective as plerixafor administration at 11 hours prior to apheresis.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Autologous donors age 18 to 75 years with NHL or MM scheduled to undergo peripheral blood stem cell collection as part of standard clinical care. Biopsy-confirmed diagnosis of NHL or MM is to have been done prior to the first mobilization.
- •In first or second CR or PR
- •ECOG performance status of 0 or 1
- •WBC count greater than 2.5 x 10e9/1
- •Absolute PMN count greater than 1.5 x 10e9/1
- •PLT count greater than 100 x 10e9/1
- •Serum creatinine less than or equal to 2.2 mg/dl
- •SGOT, SGPT, and total bilirubin less than 2.5 X upper limit of normal (ULN)
- •Cardiac and pulmonary status sufficient to undergo apheresis and transplantation
- •Negative for HIV
- •4 weeks since last cycle of chemotherapy. (Rituximab, thalidomide, dexamethasone, and bortezomib are not considered chemotherapy for the purpose of the study)
- •Patients of childbearing potential agree to use an approved form of contraception
- •Recovered from all acute toxic effects of prior chemotherapy
Exclusion Criteria
- •Comorbid condition which renders patient, in view of the investigators, at high risk of treatment complications
- •Failed previous stem cell collections or collection attempts
- •Less than 6 weeks of carmustine prior to the 1st dose of G-CSF
- •Received GM-CSF or pegfilgrastim within 3 weeks prior to the 1st dose of G-CSF for mobilization
- •Received G-CSF within 14 days prior to the 1st dose of G-CSF for mobilization
- •Active CNS involvement
- •Active brain metastases or carcinomatous meningitis
- •Bone marrow involvement greater than 20 percent
- •Received radiation therapy to the pelvis
- •Post-transplant chemotherapy and/or radiation therapy below the diaphragm is anticipated
- •Received prior radio-immunotherapy with Zevalin or Bexxar
- •Fever (temperature greater than 38 C/100.4 F)
- •Received bone-seeking radionuclides (e.g., holmium)
- •A residual acute medical condition resulting from prior chemotherapy
- •Active brain metastases or myelomatous meningitis
- •Received thalidomide, dexamethasone and/or Velcade within 7 days prior to the first dose of G-CSF
- •Received Revlimid within 3 weeks prior to the first dose of G-CSF
- •Received greater than 6 cycles of Revlimid
- •Positive pregnancy test or lactating
- •Active infection requiring antibiotic treatment
- •Abnormal ECG with clinically significant rhythm disturbance (ventricular arrhythmias), or other conduction abnormality in the last year that in the opinion of the investigator warrants exclusion of the subject from the trial.
- •Patients who previously received experimental therapy within 4 weeks of enrolling in this protocol or who are currently enrolled in another experimental protocol during the mobilization phase.
- •Patients whose apheresis product will be further selected and purified.
- •Prior autologous or allogeneic transplant.
Arms & Interventions
Plerixafor
Experimental
Plerixafor 16 hours
Intervention: Plerixafor (Drug)
Outcomes
Primary Outcomes
Percent of donors obtaining a minimum CD34+ cell dose of 2 x 106/kg actual recipient weight within 2 days of collection
Time Frame: After collection
Secondary Outcomes
- Median and average neutrophil and platelet engraftment(After stem cell infusion)
- Plerixafor-related toxicities(1 month after stem cell infusion)
Investigators
Patricia Shi
Assistant Professor, Hematology-Oncology
Shi, Patricia, M.D.
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).Lymphoma (Non-Hodgkin's Lymphoma)Hodgkin's Disease or Multiple MyelomaFront Line MobilizationTransplantationNCT00838357Genzyme, a Sanofi Company118
Active, not recruiting
Phase 1
Plerixafor y G-SCF para la movilización de células madre de sangre periférica para el trasplante autólogo de células madre en pacientes con linfoma no Hodgkin (LNH), enfermedad de Hodgkin (EH) o mieloma múltiple (MM). Estudio de la seguridad del trasplante autólogo en la población general.Plerixafor and G-CSF for the Mobilisation of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin Lymphoma (NHL), Hodgkin Disease (HD) or Multiple Myeloma (MM) - Safety Study in a General Autologous Transplant PopulatioMobilización de células madre a sangre periférica como fase previa al trasplante autólogo de estas células madre en pacientes con Linfoma No-Hodgkin, Enfermedad de Hodgkin o Mieloma MúltipleMobilisation of peripheral blood stem cells prior to autologous stem cell transplantation in patients with Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM)MedDRA version: 9.1Level: LLTClassification code 10029547Term: Non-Hodgkin's lymphomaMedDRA version: 9.1Level: LLTClassification code 10020206Term: Hodgkin's diseaseMedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2008-000689-21-ESGenzyme Europe BV100
Active, not recruiting
Not Applicable
Plerixafor and G-CSF for the Mobilisation of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin’s Lymphoma (NHL), Hodgkin’s Disease (HD) or Multiple Myeloma (MM) – Safety Study in a General Autologous Transplant PopulatioMobilisation of peripheral blood stem cells prior to autologous stem cell transplantation in patients with Non-Hodgkin’s Lymphoma (NHL), Hodgkin’s Disease (HD) or Multiple Myeloma (MM).MedDRA version: 9.1Level: LLTClassification code 10029547Term: Non-Hodgkin's lymphomaMedDRA version: 9.1Level: LLTClassification code 10020206Term: Hodgkin's diseaseMedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2008-000689-21-DEGenzyme Europe BV
Completed
Phase 3
Plerixafor and G-CSF for the Mobilisation of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin*s Lymphoma (NHL), Hodgkin*s Disease (HD) or Multiple Myeloma (MM) * Safety Study in a General Autologous Transplant PopulatioIn aanvulling op bovenstaande: Multipel myeloom, ziekte van Hodgkincancer of the bloodKahler`s disease10025322NL-OMON32383Genzyme4
Active, not recruiting
Not Applicable
Plerixafor and G-CSF for the Mobilisation of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin’s Lymphoma (NHL), Hodgkin’s Disease (HD) or Multiple Myeloma (MM) – Safety Study in a General Autologous Transplant PopulatioEUCTR2008-000689-21-NLGenzyme Europe BV